AEON Biopharma Reports $2.465 Million Net Income in Third Quarter
Key Facts
AEON Biopharma reported net income of $2.465 million in the third quarter of 2026, compared with a net loss of $4.538 million in the same period of 2025, according to its filing with the U.S. Securities and Exchange Commission. Basic and diluted earnings per share were $0.01, compared with a loss of $0.39 per share a year earlier. But the return to profitability did not reflect a comparable improvement in operating activity, as the company posted an operating loss of $4.483 million for the quarter. Net income was supported by a non-cash accounting gain from changes in the fair value of warrants. The results highlight the contrast between reported profit and continuing losses in the company's core business.
The gain from changes in the fair value of warrants was $7.014 million for the quarter, according to the company's filing. AEON said the impact was mainly related to a decline in the estimated value of Daewoong warrants and PIPE financing warrants, which it attributed primarily to a change in the share price. This item means net income was affected by the revaluation of financial liabilities, rather than revenue from product sales. The company said it has not generated revenue from product sales to date. It also does not expect product revenue before receiving regulatory approval and being able to market its treatment, ABP-450.
On liquidity, the financial statements showed cash and cash equivalents of $11.417 million at September 30, 2026, up from $3.006 million at December 31, 2025. The company later added about $6.2 million in gross proceeds from warrant exercises to its financing resources, according to the filing. On November 2, it reduced the exercise price of those warrants from $0.3221 to $0.20 per share. AEON said the adjustment preceded receipt of the proceeds from the exercises. The proceeds provide additional liquidity, but come from warrant exercise financing as the company continues to record operating losses.
Management warned that recurring losses and negative operating cash flows raise substantial doubt about the company's ability to continue as a going concern. It said its assessment indicates it may be unable to meet its obligations as they become due within one year of the issuance of the financial statements. The warning puts liquidity and additional financing among the risks facing the company, despite the increase in its cash balance compared with the end of 2025. The challenge is tied to the development stage of ABP-450, as the company has yet to generate revenue from product sales. Its ability to continue development remains linked to obtaining regulatory approvals and the necessary funding.
On development, AEON said the U.S. Food and Drug Administration agreed in principle to a two-stage design for a comparative pharmacodynamic study using cMAP measurement. The design begins with dose selection, then moves to a comparative assessment, while the regulator provided recommendations to strengthen the test's sensitivity. The company said prior clinical comparative data generated by Daewoong across multiple indications could be submitted as supportive evidence. This remains conditional on an appropriate scientific bridge to U.S.-licensed Botox and the current product, ABP-450. These steps provide a regulatory framework for the study, but do not mean the treatment has received marketing approval.
The company submitted an application for approval to initiate the study in the fourth quarter of 2026 and plans to begin the cMAP study in the first quarter of 2027. Execution of this timeline will be among the next milestones in the treatment program. On the stock, AEON, trading under the ticker AEON, closed at $0.1407 on November 16, compared with a close of $0.153 on November 13. The company also called a special shareholder meeting for December 15, 2026, to vote on authorizing the board to implement a reverse stock split. The filing proposes a range of two to 100 shares for one share, with implementation within 12 months of shareholder approval.